Key result
Critical care AF demands urgent cardioversion if unstable, with tailored pharmacology reserved for stable patients.
Why the study?
How should atrial fibrillation be managed in critically ill patients with or without hemodynamic instability?
How should atrial fibrillation be managed in critically ill patients with or without hemodynamic instability?
This narrative review provides a practical framework for the management of atrial fibrillation in the ICU, emphasizing that treatment choices must account for the unique hemodynamic instability and altered pharmacodynamics present in critically ill patients.
Answers are grounded in this paper and cite their sources.
Provides a practical ICU AF management framework; leaves open prospective validation amid limited high-level evidence.
Atrial fibrillation (AF) is common in ICU patients and is associated with a two- to fivefold increase in mortality. This paper provides a reappraisal of the management of AF with a special focus on critically ill patients with haemodynamic instability. AF can cause hypotension and heart failure with subsequent organ dysfunction. The underlying mechanisms are the loss of atrial contraction and the high ventricular rate. In unstable patients, sinus rhythm must be rapidly restored by synchronised electrical cardioversion (ECV). If pharmacological treatment is indicated, clinicians can choose between the rate control and the rhythm control strategy. The optimal substance should be selected depending on its potential adverse effects. A beta-1 antagonist with a very short half-life (e.g., esmolol) is an advantage for ICU patients because the effect of beta-blockade on cardiovascular stability is unpredictable in those patients. Amiodarone is commonly used in the ICU setting but has potentially severe cardiac and noncardiac side effects. Digoxin controls the ventricular response at rest, but its benefit decreases in the presence of adrenergic stress. Vernakalant converts new-onset AF to sinus rhythm in approximately 50% of patients, but data on its efficacy and safety in critically ill patients are lacking.
No takes yet. Share an insight, caveat, or question.
Arrigo et al. (2014) conducted a review in Atrial fibrillation in critically ill patients. Management of atrial fibrillation (rate vs rhythm control, electrical cardioversion) was evaluated. Management of atrial fibrillation in critically ill patients requires rapid electrical cardioversion for hemodynamically unstable cases and individualized pharmacological strategies based on adverse effect profiles for stable cases.
Synapse has enriched 10 related papers. Consider them for comparative context: